Trial Profile
A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs Upadacitinib (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors AbbVie; AbbVie Germany
- 14 Feb 2023 Planned End Date changed from 28 Aug 2024 to 21 Jul 2027.
- 14 Feb 2023 Planned primary completion date changed from 28 Aug 2024 to 21 Jul 2027.
- 27 May 2022 According to an AbbVie media release, results from the study were published in The Lancet.